Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Memphasys Ltd ( (AU:MEM) ) has provided an announcement.
Memphasys Limited has announced several board changes as it pivots towards the commercialisation of its Felix ™ System. Dr. David Ali will step down as Executive Director to focus on his role as CEO, emphasizing operational execution as the company prepares for a global market rollout. Marjan Mikel has been appointed Chair of Commercialisation to oversee strategy and market expansion, while Mathew Watkins joins as an Independent Non-Executive Director, bringing extensive ASX experience to support the company’s growth and compliance efforts. These changes are aimed at strengthening Memphasys’ ability to execute its commercialisation plan, including the European launch post CE-Mark approval.
More about Memphasys Ltd
Memphasys Limited is a company focused on the commercialisation of its patented Felix ™ System, a novel bioseparation technology for assisted reproduction. The system combines electrophoresis with proprietary size-exclusion membranes to rapidly isolate the most viable sperm cells for use in human fertility treatments. The company’s strategy involves securing contracted sales, driving adoption through clinical and distribution partnerships, and scaling production capacity to establish Felix ™ as a new global standard in sperm selection.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.46M
For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.